Not long after cutting its sales forecast for 2025, Valneva has decided to decrease its operational footprint in France by ...

This licensing deal falls under SK's wider ploy to harness the growing promise of radiopharmaceuticals within the oncology ...

The US FDA has accepted the new drug application (NDA) for BeOne Medicines’ B-cell lymphoma 2 (BCL2) inhibitor, sonrotoclax.

With a population of over 670 million people in ASEAN, the total number of patients experiencing rare diseases and conditions ...

The use of real-world evidence (RWE) began gaining traction decades ago, primarily as a response to the limitation around ...

Corstasis Therapeutics is to collaborate with CVL on the adoption and integration of the Enbumyst nasal spray into heart ...